Skip to main content

Table 3 12-month clinical follow-up

From: Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis

  Seal-wing PEB Iopromide-coated PEB EES p
Seal-wing vs. iopromide- PEB Seal-wing PEB vs. EES
Patients/lesions, n 63/64 68/74 68/74   
MACE all, n(%) 17 (26.98%) 7 (10.29%) 13 (19.12%) 0.003a 0.102a
CV death, n(%) 0 1 (1.47%) 1 (1.47%) 1.000b 1.000b
AIM, n(%) 4 (6.35%) 1 (1.47%) 1 (1.47%) 0.468b 0.468b
TVR, n(%) 13 (20.63%) 5 (7.35%) 11 (16.18%) 0.009a 0.360a
Event-free survivors, n(%) 46 (73.02%) 61 (89.71%) 55 (80.88%) 0.027a 0.666a
AP (CCS), n(%) 0–1 38 (82.61%) 48 (78.69%) 43 (78.18%) 1.000b 1.000b
2 7 (15.22%) 13 (21.31%) 12 (21.82%)
NYHA, n(%) 1 13 (28.26%) 14 (22.95%) 20 (36.36%) 1.000b 1.000b
2 31 (67.39%) 44 (72.13%) 31 (56.36%)
3 2 (4.35%) 3 (4.92%) 4 (7.27%)
  1. achi-square test; bFisher’s exact test